General Information of Drug (ID: DMJTDK9)

Drug Name
Ki16425 Drug Info
Synonyms SCHEMBL13385834
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
10367662
ChEBI ID
CHEBI:91194
CAS Number
CAS 355025-24-0
TTD Drug ID
DMJTDK9

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Investigative Drug(s)
Clinical Trial Drug(s)
Preclinical Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
LPA DMI5XR1 Discovery agent N.A. Investigative [5]
dioctanoylglycerol pyrophosphate DM0QY1V Discovery agent N.A. Investigative [2]
Drug Name Drug ID Indication ICD 11 Highest Status REF
LPA DMI5XR1 Discovery agent N.A. Investigative [6]
2-oleoyl-LPA DMN9OS1 Discovery agent N.A. Investigative [7]
dodecyl-thiophosphate DMAJVPI Discovery agent N.A. Investigative [8]
oleoyl-thiophosphate DM1TAM9 Discovery agent N.A. Investigative [8]
NAEPA DM38XWZ Discovery agent N.A. Investigative [9]
BrP-LPA DMPGEO1 Discovery agent N.A. Investigative [10]
dodecylphosphate DMPCLTW Discovery agent N.A. Investigative [11]
PMID18178086C15 DMA2OWK Discovery agent N.A. Investigative [12]
decyl dihydrogen phosphate DMNKDT5 Discovery agent N.A. Investigative [11]
GRI977143 DM3A0TE Discovery agent N.A. Investigative [13]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
SAR-100842 DMDMQW0 Fibrosis GA14-GC01 Phase 2 [14]
BMS-986020 DMHMV6E Scleroderma 4A42 Phase 2 [15]
BMS-986278 DMD27RW Pulmonary fibrosis CB03.4 Phase 2 [16]
BMS-986337 DM9GC6L Pulmonary fibrosis CB03.4 Phase 1 [17]
BMS-986202 DM8TAI9 Idiopathic pulmonary fibrosis CB03.4 Preclinical [18]
LPA DMI5XR1 Discovery agent N.A. Investigative [19]
dioctanoylglycerol pyrophosphate DM0QY1V Discovery agent N.A. Investigative [20]
2-oleoyl-LPA DMN9OS1 Discovery agent N.A. Investigative [7]
dodecyl-thiophosphate DMAJVPI Discovery agent N.A. Investigative [8]
oleoyl-thiophosphate DM1TAM9 Discovery agent N.A. Investigative [21]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
SAR-100842 DMDMQW0 Fibrosis GA14-GC01 Phase 2 [14]
LPA DMI5XR1 Discovery agent N.A. Investigative [22]
dioctanoylglycerol pyrophosphate DM0QY1V Discovery agent N.A. Investigative [20]
2-oleoyl-LPA DMN9OS1 Discovery agent N.A. Investigative [7]
dodecyl-thiophosphate DMAJVPI Discovery agent N.A. Investigative [8]
oleoyl-thiophosphate DM1TAM9 Discovery agent N.A. Investigative [8]
VPC12249 DM6F0VR Discovery agent N.A. Investigative [23]
NAEPA DM38XWZ Discovery agent N.A. Investigative [9]
dodecylphosphate DMPCLTW Discovery agent N.A. Investigative [11]
VPC32183 DMLK3I9 Discovery agent N.A. Investigative [24]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
G protein coupled receptor 87 (GPR87) TTO897C GPR87_HUMAN Antagonist [2]
Lysophosphatidate-3 receptor (LPAR3) TTE2YJR LPAR3_HUMAN Antagonist [3]
Lysophosphatidic acid receptor 1 (LPAR1) TTQ6S1K LPAR1_HUMAN Antagonist [4]
Lysophosphatidic acid receptor 2 (LPAR2) TTB7Y8I LPAR2_HUMAN Antagonist [3]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2907).
2 The orphan GPCR GPR87 was deorphanized and shown to be a lysophosphatidic acid receptor. Biochem Biophys Res Commun. 2007 Nov 23;363(3):861-6.
3 Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors. Mol Pharmacol. 2003 Oct;64(4):994-1005.
4 Targeting lysophosphatidic acid receptor type 1 with Debio 0719 inhibits spontaneous metastasis dissemination of breast cancer cells independently of cell proliferation and angiogenesis. Int J Oncol. 2012 Apr;40(4):1133-41.
5 Identification of the orphan GPCR, P2Y(10) receptor as the sphingosine-1-phosphate and lysophosphatidic acid receptor. Biochem Biophys Res Commun. 2008 Jul 11;371(4):707-12.
6 Synthesis and biological evaluation of phosphonic and thiophosphoric acid derivatives of lysophosphatidic acid. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3473-6.
7 Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species. Structure-activity relationship of cloned LPA receptors. FEBS Lett. 2000 Jul 28;478(1-2):159-65.
8 Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activ... J Med Chem. 2005 Jul 28;48(15):4919-30.
9 LPA and its analogs-attractive tools for elucidation of LPA biology and drug development. Curr Med Chem. 2008;15(21):2122-31.
10 Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo. Cancer Res. 2009 Jul 1;69(13):5441-9.
11 Fatty alcohol phosphates are subtype-selective agonists and antagonists of lysophosphatidic acid receptors. Mol Pharmacol. 2003 May;63(5):1032-42.
12 Discovery of potent LPA2 (EDG4) antagonists as potential anticancer agents. Bioorg Med Chem Lett. 2008 Feb 1;18(3):1037-41.
13 Virtual screening for LPA2-specific agonists identifies a nonlipid compound with antiapoptotic actions. Mol Pharmacol. 2012 Dec;82(6):1162-73.
14 Promising Pharmacological Directions in the World of Lysophosphatidic Acid Signaling. Biomol Ther (Seoul) 2015 January; 23(1): 1-11.
15 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
16 Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA(1)) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD). BMJ Open Respir Res. 2021 Dec;8(1):e001026.
17 ClinicalTrials.gov (NCT04550195) A Double-Blind, Placebo-Controlled, Randomized, Single and Multiple Ascending Dose Study of the Safety and Tolerability, and Pharmacokinetics (Including Food Effect, pH Effect and Japanese Bridging Study) of BMS-986337 Following Oral Administration in Healthy Participants. U.S.National Institutes of Health.
18 Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonist. J Pharmacol Exp Ther. 2011 Mar;336(3):693-700.
19 Diversity of lysophosphatidic acid receptor-mediated intracellular calcium signaling in early cortical neurogenesis. J Neurosci. 2010 May 26;30(21):7300-9.
20 Short-chain phosphatidates are subtype-selective antagonists of lysophosphatidic acid receptors. Mol Pharmacol. 2001 Oct;60(4):776-84.
21 Pharmacological tools for lysophospholipid GPCRs: development of agonists and antagonists for LPA and S1P receptors. Acta Pharmacol Sin. 2010 Sep;31(9):1213-22.
22 Molecular cloning and characterization of a novel human G-protein-coupled receptor, EDG7, for lysophosphatidic acid. J Biol Chem. 1999 Sep 24;274(39):27776-85.
23 Activity of 2-substituted lysophosphatidic acid (LPA) analogs at LPA receptors: discovery of a LPA1/LPA3 receptor antagonist. Mol Pharmacol. 2001 Dec;60(6):1173-80.
24 Initial structure-activity relationships of lysophosphatidic acid receptor antagonists: discovery of a high-affinity LPA1/LPA3 receptor antagonist. Bioorg Med Chem Lett. 2004 Jun 7;14(11):2735-40.